Open-label Treatment in Cushing's Syndrome (OPTICS)

Cortendo

Status and phase: Completed; Phase 3

Conditions: Cushing Disease; Cushing Syndrome

Treatments: Drug: Levoketoconazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT03621280

COR-2017-OLE

Details and patient eligibility

About

This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.

Full description

This is a long-term, OLE study of levoketoconazole in subjects with endogenous CS who have completed one or both parent studies or otherwise potentially qualify for this study, as defined in the eligibility criteria.

Enrollment: 51 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Completed the Extended Evaluation Phase of Study COR-2012-01 (i.e. M12)

2. Completed the Restoration Phase of Study COR-2017-01 (i.e. RES2)

   NOTE: Subjects meeting criteria 1 or 2 above who have had a break in therapy may be eligible only after discussion with the Medical Monitor. If eligible, such subjects may require re-establishment of the Therapeutic Dose via titration. All subjects who have had a break in therapy should be discussed with the Medical Monitor to determine the starting dose of levoketoconazole. Prior to resuming treatment with levoketoconazole, other therapies for Cushing's Syndrome must undergo an appropriate washout period, with minimum durations as follows:

   • Ketoconazole or metyrapone: 2 weeks;
   • Dopamine agonists: bromocriptine (2 weeks), cabergoline (8 weeks);
   • Octreotide acetate LAR, lanreotide Autogel, pasireotide LAR: 12 weeks;
   • Lanreotide SR: 8 weeks;
   • Octreotide acetate (immediate release) or short-acting pasireotide: 1 week;
   • Mifepristone (RU 486, KORLYM): 4 weeks;
   • Megestrol acetate or medroxyprogesterone acetate (and selected other synthetic progestins): 6 weeks.

3. Currently in a named patient program or other Expanded Access Program receiving levoketoconazole

4. Were levoketoconazole-naïve prior to entry and received early rescue therapy with open-label levoketoconazole in Study COR-2017-01.

5. Achieved a clinically meaningful partial response (with reduction of UFC) in Study COR-2017-01 at dose level 7 or at a maximally tolerated dose of levoketoconazole but did not meet the randomization criteria for Study COR-2017-01 at the end of the Dose Titration and Maintenance Phase when randomization was open.

6. Were levoketoconazole-naïve prior to entry and were enrolled in Study COR-2017-01 in the Dose Titration and Maintenance Phase when randomization was closed. (NOTE: Such subjects must receive at least 1 dose of levoketoconazole before transitioning to this study.)

Exclusion criteria

1. Discontinued levoketoconazole while participating in Study COR-2012-01 or Study COR-2017-01 or a named patient program or other Expanded Access program, due to safety or tolerability concerns or lack of efficacy.
2. Scheduled for surgery for treatment of CS or received surgery for treatment of CS within the 6 weeks prior to Screening.
3. Treated with mitotane within 6 months prior to enrollment.
4. History of malignancy, including adrenal or pituitary carcinomas (other than low-risk, well-differentiated carcinomas of thyroid, breast or prostate that are very unlikely to require further treatment in the opinion of the treating physician, or squamous cell or basal cell carcinoma of the skin).

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

51 participants in 1 patient group

Levoketoconazole

Experimental group

Description:

Levoketoconazole taken twice daily up to 1200 mg daily

Treatment:

Drug: Levoketoconazole